Biogen
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Biogen and other ETFs, options, and stocks.About BIIB
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.
BIIB Key Statistics
Stock Snapshot
The current Biogen(BIIB) stock price is $192.95, with a market capitalization of 28.49B. The stock trades at a price-to-earnings (P/E) ratio of 20.71.
During the trading session on 2026-05-17, Biogen(BIIB) shares reached a daily high of $194.89 and a low of $190.72. At a current price of $192.95, the stock is +1.2% higher than the low and still -1.0% under the high.
Trading volume for Biogen(BIIB) stock has reached 1.18M, versus its average volume of 1.19M.
The stock's 52-week range extends from a low of $121.05 to a high of $205.97.
The stock's 52-week range extends from a low of $121.05 to a high of $205.97.
BIIB News
Advertisement Why Apellis Pharmaceuticals (APLS) Is On Investors’ Radar Apellis Pharmaceuticals (APLS) has drawn fresh attention after being acquired by Bioge...
Biogen (NasdaqGS:BIIB) is advancing its experimental Alzheimer’s drug diranersen into late stage trials after Phase 2 CELIA data. The therapy, an antisense oli...
Analyst Salveen Richter of Goldman Sachs maintained a Buy rating on Biogen, boosting the price target to $250.00. Claim 55% Off TipRanks Unlock hedge fund-level...
Analyst ratings
53%
of 38 ratingsMore BIIB News
Evan Seigerman, an analyst from BMO Capital, maintained the Hold rating on Biogen. The associated price target remains the same with $196.00. Unlock hedge fund...
Evercore ISI resumed coverage of Biogen (BIIB) with an Outperform rating. Biogen’s recent update “brings a mix of insights regarding the tau program for Alzheim...
Morgan Stanley analyst Terence Flynn maintained a Hold rating on Biogen yesterday and set a price target of $206.00. Claim 55% Off TipRanks Unlock hedge fund-le...
Michael Yee, an analyst from UBS, maintained the Buy rating on Biogen. The associated price target remains the same with $225.00. Unlock hedge fund-level data...
Bank of America Securities analyst Jason Zemansky maintained a Hold rating on Biogen yesterday and set a price target of $203.00. Claim 55% Off TipRanks Unlock...
H.C. Wainwright views Biogen’s (BIIB) CELIA topline results as “historic,” noting that diranersen is the first tau-targeting therapy to demonstrate both replica...
Key Points Biogen will likely benefit from increased sales of its Alzheimer's therapy, Leqembi. Both companies have been active in acquisitions. Novo Nordisk...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.